奥比帕利联合达塞布韦治疗基因1型丙型肝炎病毒感染患者的进展  

Advances in combination therapy of ombitasvir and dasabuvir for chronic hepatitis C virus genotype 1 infection

作　　者：宁会彬 刘俊平[1] 肖二辉[1] 李宽[1] 尚佳[1] Ning Huibin;Liu Junping;Xiao Erhui;Li Kuan;Shang Jia(Department of Infectious Disease,Henan Provincial People＇s Hospital,Zhengzhou 450003,China)

机构地区：[1]河南省人民医院感染科,郑州450003

出　　处：《中华肝脏病杂志》2018年第9期710-713,共4页Chinese Journal of Hepatology

基　　金：河南省卫生厅医学科技攻关计划项目（201401015）;河南省科技厅医学科技攻关计划项目（152102310135）

摘　　要：自2014年全口服不含干扰素的直接抗病毒方案在美国、欧洲陆续获批准，基因1型丙型肝炎病毒感染患者的持续病毒学应答率提高到90％以上，慢性丙型肝炎基因1型的治疗进入了一个新的时代。作为第一个全新的直接抗病毒药物组合，奥比帕利联合达塞布韦于2015年经食品和药品管理局批准治疗基因1型慢性丙型肝炎患者，其持续病毒学应答率高、安全性好，在我国具有较好的应用前景。现对该治疗方案的药代动力学、药物相互作用、疗效及安全性等方面进行综述。Since 2014, the United States and Europe has approved all oral, interferon free- regimens that combine with direct-acting antiviral agents. Hence, the sustained virological response rate of patients with chronic HCV genotype 1 infection has improved over 90%, and the treatment modalities has introduced a new era. These drugs, ombitasvir and dasabuvir, received customary authorization of Food and Drug Administration in 2015 and are the first combined direct-acting antiviral agents for treating HCV genotype 1 infection. It has superior application prospects in China because of its high-sustained virological response rate and safety profile. This article reviews the pharmacokinetics, drug interactions, efficacy and safety of this therapeutic regimen.

关 键 词：肝炎病毒 丙型 直接抗病毒药物 治疗 

分 类 号：R512.63[医药卫生—内科学]